Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties
- PMID: 21394633
- DOI: 10.1007/s00213-011-2247-y
Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties
Abstract
Rationale: There is increasing interest in antipsychotics intended to manage positive symptoms via D(2) receptor blockade and improve negative symptoms and cognitive deficits via 5-HT(1A) activation. Such a strategy reduces side-effects such as the extrapyramidal syndrome (EPS), weight gain, and autonomic disturbance liability.
Objective: This study aims to review pharmacological literature on compounds interacting at both 5-HT(1A) and D(2) receptors (as well as at other receptors), including aripiprazole, perospirone, ziprasidone, bifeprunox, lurasidone and cariprazine, PF-217830, adoprazine, SSR181507, and F15063.
Methods: We examine data on in vitro binding and agonism and in vivo tests related to (1) positive symptoms (e.g., psychostimulant-induced hyperactivity or prepulse inhibition deficit), (2) negative symptoms (e.g., phencyclidine-induced social interaction deficits and cortical dopamine release), and (3) cognitive deficits (e.g., phencyclidine or scopolamine-induced memory deficits). EPS liability is assessed by measuring catalepsy and neuroendocrine impact by determining plasma prolactin, glucose, and corticosterone levels.
Results: Compounds possessing "balanced" 5-HT(1A) receptor agonism and D(2) antagonism (or weak partial agonism) and, in some cases, combined with other beneficial properties, such as 5-HT(2A) receptor antagonism, are efficacious in a broad range of rodent pharmacological models yet have a lower propensity to elicit EPS or metabolic dysfunction.
Conclusions: Recent compounds exhibiting combined 5-HT(1A)/D(2) properties may be effective in treating a broader range of symptoms of schizophrenia and be better tolerated than existing antipsychotics. Nevertheless, further investigations are necessary to evaluate recent compounds, notably in view of their differing levels of 5-HT(1A) affinity and efficacy, which can markedly influence activity and side-effect profiles.
Similar articles
-
Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.Behav Brain Res. 2015 May 15;285:165-75. doi: 10.1016/j.bbr.2014.09.040. Epub 2014 Oct 16. Behav Brain Res. 2015. PMID: 25448429
-
The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.Curr Opin Investig Drugs. 2010 Jul;11(7):802-12. Curr Opin Investig Drugs. 2010. PMID: 20571976 Review.
-
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.Br J Pharmacol. 2007 May;151(2):266-77. doi: 10.1038/sj.bjp.0707160. Epub 2007 Mar 20. Br J Pharmacol. 2007. PMID: 17375085 Free PMC article.
-
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.Br J Pharmacol. 2007 May;151(2):253-65. doi: 10.1038/sj.bjp.0707159. Epub 2007 Mar 20. Br J Pharmacol. 2007. PMID: 17375086 Free PMC article.
-
Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation.Neurobiol Learn Mem. 2014 Apr;110:72-80. doi: 10.1016/j.nlm.2013.12.015. Epub 2014 Jan 11. Neurobiol Learn Mem. 2014. PMID: 24423786 Review.
Cited by
-
Augmentation therapy with serotonin1A receptor partial agonists on neurocognitive function in schizophrenia: A systematic review and meta-analysis.Schizophr Res Cogn. 2023 Sep 14;34:100290. doi: 10.1016/j.scog.2023.100290. eCollection 2023 Dec. Schizophr Res Cogn. 2023. PMID: 37732133 Free PMC article.
-
In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.Int J Neuropsychopharmacol. 2023 Sep 25;26(9):599-606. doi: 10.1093/ijnp/pyad049. Int J Neuropsychopharmacol. 2023. PMID: 37549917 Free PMC article.
-
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia.CNS Drugs. 2023 Jul;37(7):545-570. doi: 10.1007/s40263-023-01022-7. Epub 2023 Jul 20. CNS Drugs. 2023. PMID: 37470979 Free PMC article. Review.
-
Seasonality of brain function: role in psychiatric disorders.Transl Psychiatry. 2023 Feb 22;13(1):65. doi: 10.1038/s41398-023-02365-x. Transl Psychiatry. 2023. PMID: 36813773 Free PMC article. Review.
-
Effect of 5-HT1A Receptor Partial Agonists of the Azapirone Class as an Add-On Therapy on Psychopathology and Cognition in Schizophrenia: A Systematic Review and Meta-Analysis.Int J Neuropsychopharmacol. 2023 Apr 17;26(4):249-258. doi: 10.1093/ijnp/pyad004. Int J Neuropsychopharmacol. 2023. PMID: 36721972 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources